Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
4.070
+0.090 (2.26%)
May 14, 2026, 4:00 PM EDT - Market closed
Cellectis Revenue
Cellectis had revenue of $7.55M in the quarter ending March 31, 2026, a decrease of -37.25%. This brings the company's revenue in the last twelve months to $75.11M, up 37.20% year-over-year. In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth.
Revenue (ttm)
$75.11M
Revenue Growth
+37.20%
P/S Ratio
4.03
Revenue / Employee
$328,000
Employees
229
Market Cap
302.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Editas Medicine | 38.69M |
| OmniAb | 28.94M |
| Zentalis Pharmaceuticals | 26.87M |
| AC Immune | 4.62M |
CLLS News
- 2 days ago - Cellectis (CLLS) Announces Clinical Trial Presentations at EHA Congress - GuruFocus
- 2 days ago - Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress - TheFly
- 2 days ago - Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - GlobeNewsWire
- 2 days ago - Cellectis (CLLS) Reports Strong Cash Position for Future Operations - GuruFocus
- 2 days ago - Cellectis (CLLS) Reports Q1 Revenue and Highlights Future Developments - GuruFocus
- 2 days ago - Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year - TheFly
- 2 days ago - Cellectis sees cash runway into 4Q27 - TheFly
- 3 days ago - Cellectis Reports Financial Results for the First Quarter 2026 - GlobeNewsWire